Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Core Insights - New data from the RELIEVE UCCD phase 2b study indicates that duvakitug shows significant potential as a treatment for ulcerative colitis (UC) and Crohn's disease (CD), with promising clinical remission and endoscopic response rates compared to placebo [1][6][9] Ulcerative Colitis (UC) Findings - In the UC cohort, 36% of patients on the 450 mg dose and 48% on the 900 mg dose achieved clinical remission at week 14, compared to 20% on placebo, with placebo-adjusted rates of 16% and 27% respectively [2][4] - Higher clinical remission rates were observed in both advanced therapy (AT)-experienced and AT-naïve subgroups [3][7] Crohn's Disease (CD) Findings - In the CD cohort, 26% of patients on the 450 mg dose and 48% on the 900 mg dose achieved endoscopic response at week 14, compared to 13% on placebo, with placebo-adjusted rates of 13% and 35% respectively [5][8] - Similar to UC, higher endoscopic response rates were noted in both AT-experienced and AT-naïve subgroups [5][8] Safety Profile - Duvakitug was generally well tolerated in both UC and CD cohorts, with no emergent safety signals or dose-dependent adverse events reported [9][10] Study Design and Objectives - The RELIEVE UCCD study was a 14-week, randomized, double-blinded, dose-ranging trial aimed at assessing the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in adults with moderate-to-severe UC or CD [11][12] - The study included a diverse patient population across multiple regions, including the US, Europe, Israel, and Asia [13] Future Development - The findings from the RELIEVE UCCD study will inform a phase 3 program anticipated to start in the second half of 2025, indicating a commitment to further investigate the efficacy and safety of duvakitug [6][16]